CN106857855B - Infant formula milk powder rich in milk fat globule membrane and structural fat OPO and preparation method thereof - Google Patents
Infant formula milk powder rich in milk fat globule membrane and structural fat OPO and preparation method thereof Download PDFInfo
- Publication number
- CN106857855B CN106857855B CN201611180120.XA CN201611180120A CN106857855B CN 106857855 B CN106857855 B CN 106857855B CN 201611180120 A CN201611180120 A CN 201611180120A CN 106857855 B CN106857855 B CN 106857855B
- Authority
- CN
- China
- Prior art keywords
- infants
- opo
- milk
- percent
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to infant formula milk powder rich in milk fat globule membrane and structural fat OPO and a preparation method thereof. The infant formula milk powder contains 0.146-0.438 percent of total MFGM-protein and 2.07-5.17 percent of structure fat OPO; the infant formula milk powder prepared by taking raw milk as a main raw material and adding whey protein powder rich in MFGM, mixed vegetable oil (rich in structural fat OPO), common whey protein powder, lactose, oligosaccharides, minerals, vitamins and some optional nutritional ingredients (choline, inositol, taurine, carnitine and the like) for ingredient standardization has the effect of promoting the growth and development of infants. The formula is suitable for developing formula milk powder for infants and older infants.
Description
Technical Field
The invention belongs to the technical field of formula milk powder, and particularly relates to infant formula milk powder rich in milk fat globule membrane and structural fat OPO and a preparation method thereof.
Background
At present, the breast-feeding rate of infants in 0-6 months in China, particularly the pure breast-feeding rate, is still low, and formula milk powder becomes a choice which parents of infants have to make. The production of the infant milk powder in China is the same as that of most countries in the world, the formula is designed and formulated mainly by referring to the components of the milk related to WHO and the components of the infant formula milk powder in Europe and America, and the national standard is formulated. However, whether the infant is suitable for the nutritional and health needs of Chinese infants or not is still lack of relevant research. With the intensive research on the components of the breast milk in recent years, the content of a plurality of functional components in the breast milk and the beneficial effect on the growth and development of infants are not comparable with those of the cow milk. Therefore, the formula milk powder which is helpful for the growth and development of infants is necessary to be developed in a targeted way.
Disclosure of Invention
The invention aims to provide infant formula milk powder rich in Milk Fat Globule Membrane (MFGM) and structural lipid OPO (namely 1, 3-dioleate-2-palmitic acid triglyceride) and a preparation method thereof, wherein whey protein powder rich in milk fat globule membrane and mixed vegetable oil rich in structural lipid OPO are specially added into the infant formula milk powder to improve the content of MFGM-protein, lactoferrin, phospholipids, ganglioside, sphingomyelin, sialic acid and the like in the infant formula milk powder and 1, 3-dioleate-2-palmitic acid triglyceride in fat, so that the purposes of promoting the body and skeleton development of infants, improving the feeding comfort of the infants and reducing the incidence rate of intestinal diseases are achieved, and the formula milk powder is suitable for infants (0-6 months old) and older infants (6-12 months old).
The invention adopts the following technical scheme:
a formula milk powder composition for promoting infant growth comprises whey protein powder rich in milk fat globule membrane 20-80 weight parts, and mixed vegetable oil rich in structural fat OPO 80-300 weight parts.
Preferably, the active ingredients of the formula milk powder composition for promoting the growth and development of infants comprise 25-75 parts by weight of whey protein powder rich in milk fat globule membranes and 250 parts by weight of mixed vegetable oil rich in structural fat OPO.
Further preferably, the active ingredients of the formula milk powder composition for promoting the growth and development of the infants comprise 43 parts by weight of whey protein powder rich in milk fat globule membranes and 203 parts by weight of mixed vegetable oil rich in structural fat OPO.
Further, the functional active ingredients in the MFGM-rich whey protein powder are as follows by mass percent:
3-7% of total MFGM-protein,
5 to 9 percent of phospholipid,
0.5 to 3 percent of sphingomyelin,
1 to 3 percent of sialic acid,
0.5 to 2 percent of total lactoferrin,
2-6% of immunoglobulin IgG,
0.5 to 2 percent of milk agglutinin,
ganglioside 0.1-0.5%,
MUC1/Mucin1 1-3％。
the MUC1/Mucin1 is Mucin-1 (MUC1/Mucin 1).
Furthermore, the functional active ingredients in the MFGM-rich whey protein powder are as follows by mass percent:
5.84 percent of total MFGM-protein,
7 percent of phospholipid,
1.6 percent of sphingomyelin,
2 percent of sialic acid,
0.8 percent of total lactoferrin,
4 percent of immunoglobulin IgG,
1 percent of milk agglutinin,
0.2 percent of ganglioside,
MUC1/Mucin1 1.4％。
the MFGM-rich whey protein powder can be prepared by a conventional method in the prior art.
The invention also provides a preparation method of the whey protein powder rich in MFGM, which comprises the following steps: pasteurizing raw milk (preferably at 72-85 deg.C for 5-15s), removing cheese or casein to obtain whey liquid; removing casein particles, fat and residues from the whey liquid; removing cream in whey by heat treatment (preferably 60-75 deg.C, 3-5min) to obtain whey material; heating the whey to 50-55 deg.C, filtering with ceramic membrane, re-filtering, heat treating the filtrate again (preferably 60-75 deg.C, 3-5min), and spray drying.
The obtained whey can be refrigerated at 4-6 deg.C before filtration for use.
The process flow chart of the preparation method of the whey protein powder rich in MFGM is shown in figure 1.
The main difference between the whey protein powder, in particular the whey protein powder prepared by the method, and the common protein powder is that the contents of functional active ingredients (MFGM protein, phospholipid, sphingomyelin, sialic acid, lactoferrin, immunoglobulin IgG, milk agglutinin, ganglioside and MUC1 protein) are relatively increased, while the 9 functional activities in the common whey protein powder are at trace or trace levels, and the content variation range of the specific functional active ingredients is shown in Table 1.
TABLE 1 relative content of functional active ingredients in whey protein powder rich in MFGM
Further, in the mixed vegetable oil rich in the structural fat OPO of the invention: the mass fraction of the structural lipid OPO is more than or equal to 17 percent, and the mass fraction of Sn-2 palmitic acid/total palmitic acid is more than or equal to 40 percent.
Furthermore, the mass fraction of the 1, 3-dioleoyl-2-palmitic acid triglyceride in the structural lipid OPO is 20-30%, and the mass fraction of the Sn-2 palmitic acid/total palmitic acid is 40-50%.
Preferably, the mass fraction of the 1, 3-dioleoyl-2-palmitic acid triglyceride in the structured fat OPO is 28.1%, and the Sn-2 palmitic acid/total palmitic acid content is 46.95%.
The structured lipid OPO can be prepared by conventional methods of the prior art.
The invention also provides a preparation method of the mixed vegetable oil rich in the structural fat OPO, which comprises the following steps: the palm oil is separated into 80 percent PPP and 20 percent POP under high melting point, then 80 percent PPP and oleic acid are mixed according to the mass ratio of 3:1, dissolved in normal hexane and subjected to grease rearrangement reaction under the action of lipase (40 ℃); after the reaction is finished, filtering to remove enzyme, distilling to remove normal hexane, and removing free fatty acid in vacuum to obtain a semi-refined product; mixing the product with mixed vegetable oil (including one or more of palm kernel oil, sunflower seed oil, soybean oil, coconut oil, etc.) and blending.
The mixed blending can be detected by gas chromatography, if the product meets the requirement, the product is refined to obtain the final product, and if the product does not meet the requirement, the product is blended, detected and analyzed again to obtain the final product.
The process flow chart of the preparation method of the mixed vegetable oil rich in the structural fat OPO is shown in figure 2.
The mixed vegetable oil rich in the structural fat OPO, in particular the mixed vegetable oil rich in the structural fat OPO prepared by the method, is mainly different from common vegetable oil and fat in that the content of 1, 3-dioleic acid-2-palmitic acid triglyceride is more than 17g/100g, and Sn-2 palmitic acid/total palmitic acid is more than 40%.
The invention also provides infant formula powder rich in MFGM and structural fat OPO, which contains the formula powder composition for helping the growth and development of infants, wherein the mass fraction of the whey protein powder rich in milk fat globule membranes in the infant formula powder is 2.0-8.0%, and the mass fraction of the mixed vegetable oil rich in structural fat OPO is 8.0-30.0%.
Preferably, the infant formula powder containing the formula powder composition for helping the growth and development of infants comprises 2.5-7.5% by mass of MFGM-rich whey protein powder and 10-25% by mass of structural fat OPO-rich mixed vegetable oil.
Preferably, the infant formula powder containing the formula powder composition for promoting the growth and development of infants is characterized in that the mass fraction of the MFGM-rich whey protein powder is 4.3%, and the mass fraction of the structural fat OPO-rich mixed vegetable oil is 20.3%.
The infant formula powder also contains a proper amount of common whey protein powder, lactose, oligosaccharides, minerals, vitamins and some optional nutritional ingredients (choline, inositol, taurine, carnitine and the like), and the adding amount of the raw materials can be calculated according to the national standard GB10765-2010 or the national standard GB 10767-2010.
Preferably, the infant formula has a total MFGM-protein mass fraction of 0.146-0.438% and a structural lipid OPO mass fraction of 2.07-5.17%.
Specifically, the infant formula powder contains the following components in percentage by mass:
0.146-0.438% of total MFGM-protein,
0.175 to 0.525 percent of phospholipid,
0.04-0.12% of sphingomyelin,
0.05 to 0.18 percent of sialic acid,
0.02 to 0.06 percent of total lactoferrin,
0.1-0.3% of immunoglobulin IgG,
0.025-0.075% of milk agglutinin,
0.005-0.015% of ganglioside,
MUC1/Mucin 0.035-0.105％，
2.07-5.17% of 1, 3-dioleic acid-2 palmitic acid triglyceride;
wherein the mass fraction of 2-position palmitic acid in the total palmitic acid is 19.7-49.24%. (specifically, the content of the extract in each 100g of milk powder.)
Preferably, the infant formula powder of the present invention comprises the following components in parts by mass:
0.251% of total MFGM-protein,
0.301 percent of phospholipid,
0.0688 percent of sphingomyelin,
sialic acid in an amount of 0.171%,
0.0344 percent of total lactoferrin,
0.172 percent of immunoglobulin IgG,
0.043 percent of milk agglutinin,
0.0086% of ganglioside,
MUC1/Mucin 0.0602％，
4.2% of 1, 3-dioleoyl-2-palmitic acid triglyceride;
wherein the mass fraction of 2-position palmitic acid in total palmitic acid is 40% (specifically, the content of each 100g of milk powder.)
The infant formula milk powder disclosed by the invention takes raw milk as a main raw material, and is prepared by adding whey protein powder rich in MFGM, mixed vegetable oil (rich in structural fat OPO), common whey protein powder, lactose, oligosaccharides, minerals, vitamins and some optional nutritional ingredients (choline, inositol, taurine, carnitine and the like) for ingredient standardization, so that the infant formula milk powder has the effect of promoting the growth and development of infants. Wherein the addition amount of the MFGM-rich whey protein powder is 25-75kg per ton of powder, and the addition amount of the structure fat OPO-rich mixed vegetable oil is 100-250 kg per ton of powder, and the content of the functional active ingredients in the formula powder obtained by the method is shown in Table 2.
TABLE 2 content of functional components in infant formula with intestinal health promoting effect
The infant milk powder of the present invention can be prepared by a conventional method of the prior art; preferably by wet processing.
Specifically, the infant formula milk powder adopts a wet processing technology, the technological process is shown in figure 3,
the method comprises the following steps: cleaning raw milk (raw milk), pre-sterilizing, mixing and standardizing, homogenizing, sterilizing, concentrating, spray-drying and the like.
The preferable main process parameters are as follows: pre-sterilization (85-88 ℃, 30 s); homogenizing 15 mPa; sterilizing (93-95 ℃ for 15 s); spray drying (inlet air temperature 150-160 deg.C, outlet air temperature 85-90 deg.C).
The invention adopts novel whey protein powder rich in Milk Fat Globule Membrane (MFGM) and mixed vegetable oil rich in structural fat OPO as raw materials, and improves the contents of bioactive substances (MFGM-protein, lactoferrin, phospholipid, ganglioside, sphingomyelin, sialic acid and the like) with special functional components and 1, 3-dioleate-2-palmitic acid triglyceride in fat through formula adjustment, thereby achieving the purposes of promoting the body and bone development of infants, improving the feeding comfort of the infants and reducing the incidence rate of intestinal diseases.
Key point of the invention
(1) The selection of raw whey protein powder rich in MFGM requires that it must meet the relative contents of several functional active ingredients listed in table 1; the raw material structural lipid OPO must be selected to meet the required content in 5.1.
(2) The addition amount of the MFGM-rich whey protein powder in the formula powder developed for infants in different stages or different constitutions needs to be changed within the range of 25-75 Kg/ton of powder according to the actual condition, and the addition amount of the structural lipid OPO needs to be changed within the range of 100-250 Kg/ton of powder according to the actual condition.
(3) In order to investigate the influence of MFGM and structural fat OPO on the development condition of the intestinal tract of the infant, the colonization condition of probiotics in the intestinal tract of the infant, the defecation condition of the infant and the incidence rate of intestinal tract diseases are comprehensively evaluated.
(4) The influence of the formula milk powder rich in MFGM and the structural fat OPO on the growth and development of the infants (physical development and skeletal development) is evaluated by using a clinical test method, and data support is provided for the clinical efficacy of the milk powder with the new formula.
The invention has the beneficial effects
The formula milk powder beneficial to the growth and development of infants is developed by adding whey protein powder rich in MFGM and structural fat OPO, so that the contents of 9 functional active ingredients of total MFGM-protein, lactoferrin, IgG, milk agglutinin, MUC1/Mucin1, phospholipid, ganglioside, sphingomyelin and sialic acid and the content of 1, 3-dioleic acid-2-palmitic acid triglyceride in fat are improved, the proportion of the functional components of the formula milk powder is closer to breast milk, and the intestinal development level and the growth and development level of infants eating the formula milk powder are closer to those of breast-fed infants. Is suitable for infant and older infant formula milk powder.
Drawings
FIG. 1 is a flow chart of a process for the preparation of MFGM enriched whey powder;
FIG. 2 is a flow chart of a process for the preparation of a mixed vegetable oil rich in structural fat OPO;
FIG. 3 is a flow chart of a process for making an infant formula with improved intestinal health;
FIG. 4 is a statistical chart of the number of patients in experiment example 3 who tested for bone density Z of three groups of infants with Z value greater than 1;
FIG. 5 is a graph comparing the stool characteristics of three groups of infants in Experimental example 3;
FIG. 6 is a graph showing a comparison of the disease state between 0 and 6 months of age in three groups of infants in Experimental example 3.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention. The examples do not show the specific techniques or conditions, according to the technical or conditions described in the literature in the field, or according to the product specifications. The reagents or instruments used are conventional products available from regular distributors, not indicated by the manufacturer.
The functional active ingredients in the whey protein powder rich in MFGM are as follows in mass fraction:
5.84 percent of total MFGM-protein,
7 percent of phospholipid,
1.6 percent of sphingomyelin,
2 percent of sialic acid,
0.8 percent of total lactoferrin,
4 percent of immunoglobulin IgG,
1 percent of milk agglutinin,
0.2 percent of ganglioside,
MUC1/Mucin1 1.4％。
the preparation method of the whey protein powder rich in MFGM comprises the following steps: pasteurizing raw milk (72-85 deg.C, 5-15s), removing cheese or casein to obtain whey liquid; removing casein particles, fat and residues from the whey liquid; removing cream in whey by heat treatment (60-75 deg.C, 3-5min) to obtain whey material; heating the whey to 50-55 deg.C, filtering with ceramic membrane, re-filtering, heat treating the filtrate again (60-75 deg.C, 3-5min), and spray drying. The obtained whey can be refrigerated at 4-6 deg.C before filtration for use. The process flow chart of the preparation method is shown in figure 1.
The following mixed vegetable oils rich in the structural fat OPO were used: the mass fraction of the structural lipid OPO is more than or equal to 17 percent, and the mass fraction of Sn-2 palmitic acid/total palmitic acid is more than or equal to 40 percent.
The preparation method of the mixed vegetable oil rich in the structural fat OPO comprises the following steps: the palm oil is separated into 80 percent PPP and 20 percent POP under high melting point, then 80 percent PPP and oleic acid are mixed according to the mass ratio of 3:1, dissolved in normal hexane and subjected to grease rearrangement reaction under the action of lipase (40 ℃); after the reaction is finished, filtering to remove enzyme, distilling to remove normal hexane, and removing free fatty acid in vacuum to obtain a semi-refined product; mixing the product with mixed vegetable oil (one or more of palm kernel oil, sunflower seed oil, soybean oil, coconut oil, etc.) and blending.
The mixed blending can be detected by gas chromatography, if the product meets the requirement, the product is refined to obtain the final product, and if the product does not meet the requirement, the product is blended, detected and analyzed again to obtain the final product. The process flow chart of the preparation method is shown in figure 2.
Example 1
A formula milk powder composition for promoting infant growth comprises 43 weight parts of whey protein powder rich in milk fat globule membrane, and 203 weight parts of mixed vegetable oil rich in structural fat OPO.
Example 2
A formula milk powder composition for promoting infant growth comprises 25 weight parts of whey protein powder rich in milk fat globule membrane and 100 weight parts of mixed vegetable oil rich in structural fat OPO.
Example 3
A formula milk powder composition for promoting infant growth and development comprises 25 weight parts of whey protein powder rich in milk fat globule membrane and 250 weight parts of mixed vegetable oil rich in structural fat OPO as effective components.
Example 4
A formula milk powder composition for promoting infant growth comprises 75 weight parts of whey protein powder rich in milk fat globule membrane and 100 weight parts of mixed vegetable oil rich in structural fat OPO.
Example 5
A formula milk powder composition for promoting infant growth and development comprises 75 weight parts of whey protein powder rich in milk fat globule membrane and 250 weight parts of mixed vegetable oil rich in structural fat OPO as effective components.
Example 6
An infant formula enriched with MFGM and structural lipid OPO comprising the formula composition for assisting the growth and development of infants described in example 1, wherein the infant formula comprises 4.3% by mass of said MFGM-enriched whey protein powder and 20.3% by mass of said structural lipid OPO-enriched mixed vegetable oil. The infant formula milk powder also contains a proper amount of common whey protein powder, lactose, oligosaccharides, minerals, vitamins and some optional nutritional ingredients (choline, inositol, taurine, carnitine and the like), and the adding amount of the raw materials is calculated according to the national standard GB10765-2010 or the national standard GB 10767-2010.
The infant formula milk powder comprises the following components in percentage by mass:
0.251% of total MFGM-protein,
0.301 percent of phospholipid,
0.0688 percent of sphingomyelin,
sialic acid in an amount of 0.171%,
0.0344 percent of total lactoferrin,
0.172 percent of immunoglobulin IgG,
0.043 percent of milk agglutinin,
0.0086% of ganglioside,
MUC1/Mucin 0.0602％，
4.2% of 1, 3-dioleoyl-2-palmitic acid triglyceride;
wherein the mass fraction of the 2-position palmitic acid in the total palmitic acid is 40% (referring to the content in each 100g of milk powder).
Example 7
An infant formula enriched in MFGM and structural lipid OPO comprising the formula composition for assisting the growth and development of infants as described in example 2, wherein the infant formula comprises 2.5% by mass of said MFGM-enriched whey protein powder and 10% by mass of said structural lipid OPO-enriched mixed vegetable oil. The infant formula milk powder also contains a proper amount of common whey protein powder, lactose, oligosaccharides, minerals, vitamins and some optional nutritional ingredients (choline, inositol, taurine, carnitine and the like), and the adding amount of the raw materials is calculated according to the national standard GB10765-2010 or the national standard GB 10767-2010.
Example 8
An infant formula enriched in MFGM and structural lipid OPO comprising the formula composition for assisting growth and development of infants as described in example 5, wherein the infant formula comprises 7.5% by mass of said MFGM-enriched whey protein powder and 25% by mass of said structural lipid OPO-enriched mixed vegetable oil. The infant formula milk powder also contains a proper amount of common whey protein powder, lactose, oligosaccharides, minerals, vitamins and some optional nutritional ingredients (choline, inositol, taurine, carnitine and the like), and the adding amount of the raw materials is calculated according to the national standard GB10765-2010 or the national standard GB 10767-2010.
The experimental method used in the invention is as follows:
1 product nutritional quality and safety detection
The detection of the nutritional index, the physicochemical index, the microbial index and the sensory index of the product is strictly carried out according to the detection items and the detection methods specified by the national standard of food safety for infant formula food (GB-10765-.
Method for evaluating clinical feeding of infant formula milk powder rich in MFGM and OPO on growth and development of infants
And (3) recruiting pure breast feeding infants and pure formula milk powder feeding infants, and tracking and investigating the growth and development conditions of the infants at the age of 0-6 months. After obtaining informed consent from parents/guardians, infants were enrolled, wherein formula-fed infants were divided into two groups using a plain breast-fed group (BF) infant as a reference standard for growth and development, and plain infant milk powder (FF1) and MFGM and OPO enriched infant formula (FF2, prepared in experimental example 1) were administered to the enrolled infants in a randomized, double-blind manner, respectively.
2.1 examination of the physical development of infants
The weight and length of the infant is measured from birth to 6 months of age per month, and the measurement is performed by professional medical staff. The multifunctional mother-infant scale is adopted for measurement, and the maximum measuring range of the instrument is as follows: 100kg, minimum range: 0.7kg, precision 0.1 kg. Body length measurement range: 41cm-85cm, and the measurement precision is 0.1 cm.
And after acquiring the body length and weight data of the infant at each month of age, evaluating the growth and development level and the nutritional status of the infant by using a Z value method. The Z scoring method is currently the most commonly used method. In this study, the nutritional status of the infant group was evaluated using the Z-value calculated by WHO's Anthro (version3.2.2, April2011) software.
2.2 evaluation of infant comfort
The parents fill out the follow-up survey form to record the situations of milk returning, milk choking and vomiting after feeding every time in each half month of the babies and the situations of times of crying with unknown reasons in the near term. And (4) recovering the questionnaire every month for computer entry, and performing statistical analysis after tracking.
2.3 examination of bone Density
The operation of the ultrasonic bone densitometer (Sunlight Miniomni) is completed by professional medical staff at 6 months of age of the infant. The evaluation of the skeletal development of the infant is carried out by the Z value measured by the instrument: wherein-1 < Z value < 0: normal range, below average; 0< Z value < 1: normal range, above average; -2< Z value < -1: low bone density, recommended diet and supplement adjustments; -3< Z value < -2: the bone density is very low, the hospital is recommended to review and treat the disease; 1< Z value: the bone density is good and keeps.
2.4 evaluation of intestinal development status of infants
2.4.1 colonization of intestinal tracts by bifidobacteria and lactobacilli
A high-throughput gene sequencing platform is adopted, and the relative abundance of bifidobacteria and lactobacilli in intestinal flora of the three groups of infants is examined by detecting a 16S rDNA V3+ V4 region. The DNA extraction of the infant feces is completed by adopting a feces genome extraction kit (DP328) (Tiangen Biochemical technology Co., Ltd., China) according to the instruction; sequencing by adopting Miseq after the library is constructed, wherein the sequencing strategy is PE 250; and (3) finishing data filtering by removing low-quality bases, Ns, linker pollution sequences and other processes to obtain a credible target sequence (clear Reads) for subsequent analysis. The corresponding Read1 and Read2 of paired-end sequencing were then spliced using the sequence splicing method PEAR. The spliced sequence was analyzed using version of software QIME 1.8.0.
2.4.2 infant defecation examination
The parents fill out a follow-up questionnaire to record the defecation frequency and the stool characteristics of the infant, wherein the stool characteristics mainly comprise: water sample, loose stool, semi-forming, forming and dry and hard. And (4) recovering the questionnaire every month for computer entry, and performing statistical analysis after tracking.
2.5 two week prevalence
Parents record the times of respiratory diseases, intestinal diseases and skin diseases of infants in every two weeks through follow-up questionnaires, a calculation formula is shown as follows, and the inhibition effect of the milk powder with the new formula on the intestinal diseases of the infants is investigated through the morbidity of the infants in the two weeks. Comparisons between groups were performed using the Cruskal-wallis rank sum test.
Experimental example 1 design of formula 1 segment for infants of 0-6 months of age with promotion of infant growth
Particularly, whey protein powder rich in MFGM and specially prepared structural fat OPO from cow milk are selected, wherein the content of 9 functional components in the whey powder is shown in table 3; the content of 1, 3-dioleoyl-2-palmitic acid triglyceride in the structural fat OPO is 28.1g/100g, and the proportion of Sn-2 palmitic acid in palmitic acid is 46.95%.
The formula milk powder which is suitable for 0-6 months old and rich in MFGM and structural lipid OPO and can promote the growth and development of infants is designed by taking raw milk as a main raw material, specifically adding whey protein powder rich in MFGM (the addition amount is 43Kg per ton of powder) and specifically blending structural lipid OPO (the addition amount is 203Kg per ton of powder), and other main ingredients comprise lactose, whey protein powder (containing alpha-lactalbumin), galacto-oligosaccharide (GOS), fructo-oligosaccharide (FOS), Polyfructose (Polyfructose), docosahexaenoic acid (DHA, source schizochytrium), arachidonic acid (ARA), taurine, minerals, vitamins, nucleotides, L-carnitine tartrate, casein phosphopeptides (CPP) and lutein, wherein the content of main macronutrients is shown in Table 4. Table 5 shows the comparison of the content of 9 functional active ingredients introduced from whey powder in the breast milk, the formula of the present invention and the general control group, and it can be seen from table 5 that the content of 9 functional active ingredients in the formula after adding MFGM-rich whey protein is higher than that of the control formula milk powder group and it is closer to the content of these functional active ingredients in the breast milk group.
TABLE 3 relative content of functional active ingredients in milk-derived MFGM enriched whey protein powder
TABLE 4 Table of the main macronutrients in infant formula powder with intestinal health promoting effect
TABLE 5 functional active ingredient content in infant formula powder with intestinal health promoting effect
Experimental example 2 product nutritional quality and safety test
The formula milk powder which is prepared in the experimental example 1 and is added with the MFGM-rich whey egg powder and the structural fat OPO and has the effect of promoting the growth and development of infants is subjected to item-by-item inspection according to the requirements of the national food safety standard infant formula food (GB-10765-.
Experimental example 3 clinical feeding evaluation of infant formula powder enriched with MFGM and OPO on the growth and development of infants
Experimental example 1 Effect of MFGM and OPO enriched infant formulas prepared in accordance with Experimental example 1 on the physical development of infants
The collected weight and length data of the infants at each month age are compared with the WHO recommended value, and the weight and length of the infants, whether male infants or female infants, change along with the month age and exceed or accord with the WHO recommended standard value (data are not shown). The result of analyzing the Z value of the growth and development of the infant is as follows:
WAZ can be used as a dynamic monitoring indicator of child growth. WAZ is commonly used internationally as the basis for judging the prevalence rate of malnutrition, and WAZ < -2 > is low body weight. It can be seen from table 6 that the WAZ values for all three groups of infants were greater than-2 at each month of age, indicating that there were no low weight infants in this study. However, WAZ values of the infants fed with the milk powder in the two groups are negative numbers at birth, and after analysis of formula difference, the infants fed with the milk powder are found to have significantly lower overall nutrition status than the infants fed with the milk (P <0.05) at birth, and the significant difference lasts until the infants are 2 months old. Comparing WAZ values of infants in both formula groups, it was found that at birth, the average WAZ value of FF2 group was lower than that of FF1 group, but WAZ value of FF2 group was already 2 times higher than that of FF1 group after 2 months of feeding and was slightly lower than that of breast feeding group. The differences between the groups disappeared from 3 months of age, and the nutritional status of the infants in the three groups did not differ significantly (P > 0.05). This indicates that both formulas contribute to the improvement of the nutritional level of the infant and to the restoration of the overall nutritional status to the level of breast-fed infants for infants with a moderate development level at birth.
Meanwhile, Table 7 compares the growth rates of three infants at 6 months of age, in which WT0 and WT6 represent the body weights at birth and at 6 months of age, respectively, and WAZ0 and WAZ6 represent the Z values of W/A, respectively; Δ WAZ represents the difference between WAZ6 and WAZ 0. Analysis of variance showed significant differences in body weight WTO and age-related body weight WAZ0 at birth for the three groups of infants, but no significant difference in Δ WAZ (p > 0.05) between the three groups after 6 months of feeding, indicating that the growth rate of the two formula-fed infants was not significantly different from that of the breast-fed group.
Further, the overall nutrition and health status of the infants were evaluated comprehensively by BAZ values, and the results are shown in Table 8. It can be seen from the table that the BAZ values of the infants in FF2 group were not significantly different in all three groups at the age of 3 months, except that the BAZ values were significantly higher in the infants in BF group and FF1 group at the age of 3 months.
The analysis shows that the formula milk powder rich in MFGM and OPO prepared in the experimental example 1 has obvious promotion effect on the physical development of the infants, and can keep the overall nutrition and health conditions of the infants to be not obviously different from those of breast-fed infants.
TABLE 6 comparison of WAZ values for infants within 0-6 months of age
TABLE 7 weight growth level and growth Rate for infants aged 0-6 months
TABLE 8 comparison of BAZ values for infants 0-6 months of age with different feeding regimes
Evaluation of comfort of formula in infants
2.1 Choking milk
The proportion of milk choking phenomenon after daily feeding of infants is counted, and the inter-group difference analysis is carried out by a chi-square test. It can be seen from Table 9 that the ratio of infants who did not develop milk choking during feeding increased with age of the month in all three groups, indicating that the infants started to practice and master the method of sucking nipple or nipple from birth, and that about 50% or more infants did not develop milk choking at 1 month of age to 95% or more infants did not develop milk choking at 6 months of age. Comparing the milk choking condition of three groups of infants at each month, it is found that 90% of the infants in FF1 group are free from milk choking at 3 months, and 90% of the infants in BF group and FF2 group are free from milk choking at 5 months. The result shows that the two formulas do not cause the phenomenon of severe milk choking of the infant caused by the problems of milk powder design or raw material selection and the like, and the frequency of the milk choking phenomenon of the infant fed by the formulas is consistent with that of the milk fed by the infant, and both are within an acceptable range.
TABLE 9 statistical analysis of the absence of milk choking after feeding breast milk or milk powder to infants
2.2 delactation
The phenomenon of milk regurgitation is caused by the fact that the gastrointestinal tract of the infant is in the development stage and the milk or the formula milk powder cannot be completely digested, and on the other hand, the phenomenon of milk regurgitation is also an important index for evaluating the safety and the formula scientificity of the formula milk powder. It can be seen from table 10 that the ratio of severe milk regurgitation (average number of milkings per day greater than 2) in both groups of formula-fed infants in this study was not significantly different from that in the breast milk group, indicating that the formula of both formulas was scientifically and reasonably designed and satisfactory for the fragile intestinal comfort of the developing infants.
TABLE 10 statistical analysis of the occurrence of the phenomenon of milk regurgitation after feeding breast milk or milk powder to infants
2.3 vomiting
As is clear from Table 11, the rate of non-vomiting among the three infants was 60% from birth to 1 month of age, and the rate of non-vomiting among the three infants gradually increased with age. It is particularly noted that the satisfaction of the FF2 group was more than 90% at 4 months of age, comparable to the BF group, and significantly higher than the FF1 group, and that this significant difference continued to 6 months of age, and eventually both the satisfaction of vomiting reached more than 95% in the BF and FF2 groups at 6 months of age, while the satisfaction of the FF1 group was somewhat lower (80%) at this time.
TABLE 11 statistical analysis of absence of vomiting after feeding breast milk or milk powder to infants
2.4 Cry
The infants in this study showed significant differences in the proportion of "unexplained crying" (excluding feeding, changing diapers and stopping crying after clothes reduction/addition) "between 0-2 months of age in the three groups (as shown in table 12), and no significant difference in the proportion of crying between the three groups from 3 months of age, wherein statistics showed that the proportion of bad emotions occurred in the FF2 group and BF group infants at 1 month of age and 2 months of age was comparable, but significantly lower than that in the FF1 group infants.
TABLE 12 statistical analysis of crying phenomena of unknown origin in infants
Note: stopping crying after eliminating feeding, changing diaper and reducing/increasing clothes
The analysis shows that the formulas of the two formulas are reasonable and scientific in design, the intestinal tracts in the development period of infants have good adaptability to the two formulas, but the comfort evaluation result of the FF2 group of infants eating the formulas rich in MFGM and OPO is closer to that of breast-fed infants (BF).
3.3 Effect of MFGM and OPO enriched infant formulas on skeletal development in infants
The Z value of the bone density detection is a direct evaluation index of the skeletal development of the infant. Fig. 4 shows the results of bone density measurements at 6 months of age for three infants, from which it can be seen that the proportion of people with Z-values greater than 1 (very well developed bones) in formula fed infants was higher in the three infants than in the breast fed group, and that the proportion of people with Z-values greater than 1 in FF2 group was higher than in FF1, but there was no significant difference (P > 0.05) between the three groups after chi-square testing. The analysis reason is probably that the specially enhanced calcium and vitamin D in the formula milk powder have obvious promotion effect on the skeletal development of the infants, and the formula milk powder rich in the structural fat OPO can further promote the absorption of the calcium by the bodies of the infants, so that the proportion of the people with good skeletal development in the FF2 group to the total number of people is the highest.
3.4 Effect of MFGM and OPO enriched infant formulas on infant gut development
3.4.1 colonization of Bifidobacterium and Lactobacillus in the intestinal tract of infants
The difference between two lactic acid bacteria Lactobacillus and Bifidobacterium in the intestines of three groups of infants at each month of age was analyzed by a nonparametric assay (Cruskal-wallis rank sum assay) and the results are shown in Table 13. As can be seen from the table, the relative abundance of bifibacteriaceae in the intestinal tracts of three groups of infants has no significant difference with age; lactobacillus produces significant differences (p <0.05) between groups at 3, 4 and 5 months of age infants, the relative abundance in the intestine of group FF1 infants is significantly lower than that of the BF group, while the relative abundance of this family in the intestine of group FF2 fed infants is comparable to that of the BF group at 3 and 4 months of age and significantly lower than that of the BF group at 5 months of age. This indicates that the relative abundance of total lactic acid bacteria in the intestinal flora of group FF2 infants is closer to that of group BF.
TABLE 13 Cruskal-wallis rank sum of relative abundance at two Lactobacillaceae levels in the gut of three groups of infants
3.4.2 infant stool traits
The structural fat OPO added in the research has the functions of promoting calcium absorption and softening the feces of the infants. The study examined the change in stool characteristics from 1-month to 6-month age in three groups of infants, and the results are shown in fig. 5. As can be seen from the figure, the stool trait of breast-fed infants from 1-6 months of age gradually changed from thin stool to semi-formed, whereas the stool trait of formula-fed infants gradually changed from predominantly semi-formed to predominantly formed. However, comparison of the two groups of formula fed infants shows that the relative proportions of loose stools and semi-formed stools at 1-3 months of age were higher in the FF2 group than in the FF1 group, and that the formed stools predominated in both groups of formula fed infants by 6 months of age. This result indicates that the stool profile of the infants in FF2 group was more gradual than the transition from watery stool and semi-formed to formed in the infants in FF1 group, indicating that the intestinal comfort of infants fed the formula enriched with structural fat OPO was higher than that of infants fed the standard formula.
3.5 modulation of immune function in infants by MFGM and OPO enriched infant formulas
The development of the immune system is an important index for the healthy growth of the infants, and in the research, the two feeding modes are compared by the prevalence rate of two weeks, the prevalence conditions of three groups of infants within 0-6 months of age are indirectly compared, and the development conditions of the immune competence of the three groups of infants are indirectly compared. FIG. 6 shows the overall comparison of the disease status between 0-6 months of age of infants, from which it can be seen that the ratio of respiratory tract diseases in formula-fed infants is higher than that in breast-fed group, while the ratio of digestive tract diseases is similar to that in breast-fed group, and for skin diseases, the statistics show that the frequency of FF1 group infants is lower than that in BF group and FF2 group infants, but there is no significant difference (p > 0.05) between the incidence rates of the three diseases in the first 6 months of statistical analysis.
Although the invention has been described in detail hereinabove with respect to a general description and specific embodiments thereof, it will be apparent to those skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (2)
1. An infant formula powder rich in MFGM and structural fat OPO, which is characterized in that the mass fraction of whey protein powder rich in milk fat globule membranes in the infant formula powder is 4.3%, and the mass fraction of mixed vegetable oil rich in structural fat OPO is 20.3%; wherein the infant formula powder comprises the following components in percentage by mass:
0.251% of total MFGM-protein,
0.301 percent of phospholipid,
0.0688 percent of sphingomyelin,
sialic acid in an amount of 0.171%,
0.0344 percent of total lactoferrin,
0.172 percent of immunoglobulin IgG,
0.043 percent of milk agglutinin,
0.0086% of ganglioside,
MUC1/Mucin 0.0602％，
4.2% of 1, 3-dioleoyl-2-palmitic acid triglyceride; wherein the mass fraction of 2-position palmitic acid in the total palmitic acid is 40%;
the infant formula further comprises: lactose, whey protein powder, galacto-oligosaccharide, fructo-oligosaccharide, polyfructose, docosahexaenoic acid, arachidonic acid, taurine, minerals, vitamins, nucleotides, L-carnitine tartrate, casein phosphopeptide and lutein.
2. A method of preparing an infant formula powder according to claim 1, comprising: cleaning raw materials, pre-sterilizing, mixing, standardizing, homogenizing, sterilizing, concentrating, and spray drying; the main technological parameters are as follows: pre-sterilizing at 85-88 deg.c for 30 sec; homogenizing 15 mPa; sterilizing at 93-95 ℃ for 15 s; the air inlet temperature of spray drying is 150-160 ℃, and the air outlet temperature is 85-90 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611180120.XA CN106857855B (en) | 2016-12-19 | 2016-12-19 | Infant formula milk powder rich in milk fat globule membrane and structural fat OPO and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611180120.XA CN106857855B (en) | 2016-12-19 | 2016-12-19 | Infant formula milk powder rich in milk fat globule membrane and structural fat OPO and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106857855A CN106857855A (en) | 2017-06-20 |
| CN106857855B true CN106857855B (en) | 2021-02-02 |
Family
ID=59164770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611180120.XA Active CN106857855B (en) | 2016-12-19 | 2016-12-19 | Infant formula milk powder rich in milk fat globule membrane and structural fat OPO and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106857855B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109418396A (en) * | 2017-08-22 | 2019-03-05 | 中国农业大学 | Artificial fat drips and its application |
| CN110742130A (en) * | 2019-11-14 | 2020-02-04 | 东北农业大学 | Infant formula goat milk powder added with liposome simulating breast milk fat structure and preparation method thereof |
| CN111345351A (en) * | 2020-04-20 | 2020-06-30 | 临夏州燎原乳业有限公司 | Novel milk powder and its preparation method |
| CN112042750B (en) * | 2020-09-09 | 2022-04-05 | 北京三元食品股份有限公司 | Infant formula milk powder rich in milk fat globule membrane protein, phospholipid and oligosaccharide and preparation method thereof |
| CN115568509A (en) * | 2021-02-22 | 2023-01-06 | 北京三元食品股份有限公司 | Application of structural lipid OPL in preparation of formula milk powder for promoting proliferation of intestinal probiotics |
| CN115104731B (en) * | 2021-07-27 | 2024-04-19 | 黑龙江飞鹤乳业有限公司 | Nutritional composition and food comprising said nutritional composition |
| CN115918729A (en) * | 2022-11-07 | 2023-04-07 | 东北农业大学 | Breast milk simulated fat globule structure emulsion and preparation method thereof |
| CN115997937B (en) * | 2022-12-13 | 2024-03-12 | 黑龙江飞鹤乳业有限公司 | Nutritional composition containing milk fat globule membrane, application and food |
| CN118592494A (en) * | 2024-08-05 | 2024-09-06 | 内蒙古蒙牛乳业（集团）股份有限公司 | Application of grease composition in improving breath quality of infants or children |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105578899A (en) * | 2013-07-01 | 2016-05-11 | 英雄股份公司 | New prophylactic use for prevention of infections |
| CN106359604A (en) * | 2016-08-24 | 2017-02-01 | 北京三元食品股份有限公司 | Infant formula milk powder for improving health of intestinal tract and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080003329A1 (en) * | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Enriched infant formulas |
| CN102524421B (en) * | 2011-12-31 | 2013-05-22 | 黑龙江省完达山乳业股份有限公司 | Novel acid-base balance infant formula milk powder and preparation method thereof |
| CN106106753B (en) * | 2016-06-27 | 2019-08-06 | 黑龙江飞鹤乳业有限公司 | A kind of infant formula rich in a variety of newborn phosphatide |
-
2016
- 2016-12-19 CN CN201611180120.XA patent/CN106857855B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105578899A (en) * | 2013-07-01 | 2016-05-11 | 英雄股份公司 | New prophylactic use for prevention of infections |
| CN106359604A (en) * | 2016-08-24 | 2017-02-01 | 北京三元食品股份有限公司 | Infant formula milk powder for improving health of intestinal tract and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106857855A (en) | 2017-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106857855B (en) | Infant formula milk powder rich in milk fat globule membrane and structural fat OPO and preparation method thereof | |
| JP7210032B2 (en) | Use of lactic acid bacteria for treating or preventing at least one of postpartum depression and postpartum anxiety | |
| RU2670880C2 (en) | Source of plant-based fats | |
| JP2021152062A (en) | Synthetic composition and method for treating irritable bowel syndrome | |
| TWI418308B (en) | Stable nutritional powder | |
| TWI418307B (en) | Stable nutritional powder | |
| EP1976397B1 (en) | Infant immunological formula | |
| EP3079499B1 (en) | Synthetic milk compositions comprising polyunsaturated fatty acids (pufas) for promoting the healthy establishment of cognitive function in male and female infant and children | |
| JP2009542226A (en) | Enhanced infant formula | |
| Venkat et al. | Milk polar lipids composition and functionality: A systematic review | |
| CN115568509A (en) | Application of structural lipid OPL in preparation of formula milk powder for promoting proliferation of intestinal probiotics | |
| TW201729691A (en) | Nutritional compositions containing butyrate and uses thereof | |
| EP3079497B1 (en) | Synthetic milk compositions comprising n-6 eicosatrienoic acid and polar lipids for infants younger and older than three months for healthy establishment of cognitive function | |
| CN110337306A (en) | Alimentation composition and application thereof containing butyric acid and/or lactoferrin | |
| CN107106618B (en) | Sphingolipid absorption enhancer | |
| da Silva et al. | Technological Advances in Infant Formula Ingredients | |
| WO2024223917A1 (en) | Compositions comprising human milk oligosaccharides for use in a subject to support brain development and/or cognitive development | |
| WO2024002816A1 (en) | Fat composition to prevent infantile regurgitation | |
| Singh et al. | Development of probiotics and prebiotics product as weaning food for infants | |
| Lee | The Role of Milk Fat Globule Membrane in Sustaining Intestinal Health and Metabolism in Infancy | |
| Shama | Human Milk-based Protein Concentrate Supports Growth of Weanling Rats | |
| Traustadóttir | Þróun nýrrar mjólkurafurðar fyrir ung börn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |